Trough serum concentrations of β-lactam antibiotics in cancer patients: Inappropriateness of conventional schedules to pharmacokinetic/ pharmacodynamic properties of β-lactams

International Journal of Antimicrobial Agents

Volumn 27, Issue 2, 2006, Pages 102-107

  Navas, Dominique ^a   Caillon, Jocelyne ^a   Batard, Eric ^a   Le Conte, Philippe ^a   Kergueris, Marie France ^a   Moreau, Philippe ^a   Potel, Gilles ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Cancer patients; Cefepime; Ceftazidime; Imipenem; Trough serum concentration

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; GLYCOPEPTIDE; IMIPENEM; VANCOMYCIN;

ADULT; AGED; ARTICLE; CANCER; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BLOOD LEVEL; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 31344467318     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.09.016     Document Type: Article

References (38)

1. R. Ramphal Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens Clin Infect Dis 39 2004 S25 S31
2. N.V. Sipsas, G.P. Bodey, and D.P. Kontoyiannis Perspectives for the management of febrile neutropenic patients with cancer in the 21st century Cancer 103 2005 1103 1113
3. G.P. Bodey Pseudomonas aeruginosa infections in cancer patients: have they gone away? Curr Opin Infect Dis 14 2001 403 407
4. W.T. Hughes, D. Armstrong, and G.P. Bodey 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 34 2002 730 751
5. C. Viscoli, O. Varnier, and M. Machetti Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification Clin Infect Dis 40 2005 S240 S245
6. G.L. Drusano Role of pharmacokinetics in the outcome of infections Antimicrob Agents Chemother 32 1988 289 297
7. J.D. Turnidge The pharmacodynamics of β-lactams Clin Infect Dis 27 1998 10 22
8. R.J. Young, J. Lipman, T. Gin, C.D. Gomersall, G.M. Joynt, and T.E. Oh Intermittent bolus dosing of ceftazidime in critically ill patients J Antimicrob Chemother 40 1997 269 273
9. J. Lipman, S.C. Wallis, and C. Rickard Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrob Agents Chemother 43 1999 2559 2561
10. B. Georges, M. Archambaud, and S. Saivin Continuous versus intermittent cefepime infusion in critical care patients. Preliminary findings Pathol Biol 47 1999 483 485
11. G.L. Drusano, K.I. Plaisance, and A. Forrest Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients Antimicrob Agents Chemother 31 1987 1420 1422
12. W.T. Hughes, D. Armstrong, and G.P. Bodey Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever J Infect Dis 161 1990 381 396
13. C.M. Myers, and J.L. Blumer Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography Antimicrob Agents Chemother 26 1984 78 81
14. Comité de l'Antibiogramme de la Société Française de Microbiologie (CASFM), Janvier, 2005.
15. D.M. Cappelletty, S.L. Kang, S.M. Palmer, and M.J. Rybak Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone or in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model Antimicrob Agents Chemother 33 1995 1797 1801
16. J.W. Mouton, and A. Vinks Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations J Antimicrob Chemother 38 1996 5 15
17. M. Manduru, L.B. Mihm, R.L. White, L.V. Friedrich, P.A. Flume, and J.A. Bosso In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients Antimicrob Agents Chemother 41 1997 2053 2056
18. S.W. Lemmen, I. Engels, and F.D. Daschner Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers J Antimicrob Chemother 39 1997 841 842
19. P.R. Tessier, D.P. Nicolau, C.O. Onyeji, and C.H. Nightingale Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model Chemotherapy 45 1999 284 295
20. M.A. Robaux, L. Dube, and J. Caillon In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model J Antimicrob Chemother 47 2001 617 622
21. V.H. Tam, P.S. McKinnon, R.L. Akins, M.J. Rybak, and G.L. Drusano Pharmacodynamics of cefepime in patients with gram-negative infections J Antimicrob Chemother 50 2002 425 428
22. D. Navas, J. Caillon, and C. Gras-Le Guen Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics J Antimicrob Chemother 54 2004 767 771
23. C. Cordonnier, N. Dhedin, C. Rieux, and K. Belhagj Epidemiology of therapeutic options in neutropenic patients Presse Med 26 1997 45 50
24. P. Biron, C. Furhmann, and H. Cure Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia J Antimicrob Chemother 42 1998 511 518
25. S. Daenen, and H. de Vries-Hospers Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime Lancet 1 1988 937
26. O. Legrand, J.P. Marie, and C. Bardin Ceftazidime: avantages des perfusions continues chez un malade en aplasie Presse Med 22 1993 786
27. B. Vogelman, S. Gudmundsson, J. Leggett, J. Turnigde, S. Ebert, and W.A. Craig Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J Infect Dis 158 1988 831 847
28. W.A. Craig, and S.C. Ebert Continuous infusion of β-lactam antibiotics Antimicrob Agents Chemother 36 1992 2577 2583
29. B. Fantin, R. Farinotti, A. Thabaut, and C. Carbon Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa J Antimicrob Chemother 33 1994 563 569
30. S. Keil, and B. Wiedemann Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model Antimicrob Agents Chemother 41 1997 1215 1219
31. U. Flückiger, C. Segessenmann, and A.U. Gerber Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model Antimicrob Agents Chemother 35 1991 1905 1910
32. B. Fantin, J. Leggett, S. Ebert, and W.A. Craig Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model Antimicrob Agents Chemother 35 1991 1413 1422
33. S. Daenen, Z. Erjavec, D.R.A. Uges, H.G. De Vries-Hospers, P. De Jonge, and M.R. Halie Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia Eur J Clin Microbiol Infect Dis 14 1995 188 192
34. A.S. Benko, D.M. Cappellety, J.A. Kruse, and M.J. Rybak Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections Antimicrob Agents Chemother 40 1996 691 695
35. E. Bernard, D. Breilh, and J.P. Bru Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach Clin Microbiol Infect 9 2003 339 348
36. A.P. MacGowan, and K.E. Bowker Continuous infusion of β-lactam antibiotics Clin Pharmacokinet 35 1998 391 402
37. E. Grant, D.P. Nicolau, C.H. Nightingale, and R. Quintiliani Continuous infusion of beta-lactam antibiotics Conn Med 63 1999 275 277
38. G. Egerer, H. Goldschmidt, and H. Salwender Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation Int J Antimicrob Agents 15 2000 119 123